Two COVID-19 Vaccine Candidates Enter Human Trials, 60 in Pre-Clinical Stage - COVID-19 Clinical Trial
Breaking News | COVID-19

Two COVID-19 Vaccine Candidates Enter Human Trials, 60 in Pre-Clinical Stage

Two candidate vaccines for COVID-19 have entered the first phase of human clinical trials and another 60 candidate vaccines are in pre-clinical studies, the World Health Organization (WHO) has confirmed. The first vaccine candidate is  jointly developed by CanSino Biological Inc and Beijing Institute of Biotechnology. The other vaccine that has entered the first phase of trials is from the US-based biotech firm Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) combine. 


A Call for Blood Donations Amid the COVID-19 Crisis

The ongoing spread of the novel coronavirus (COVID-19) has caused massive cancellations in almost every aspect of life, including much-needed blood donation drives. If you are healthy and a potential blood donor, Northwell Health encourages donations at this time. Red blood cells are crucial to helping people and are in low supply due to the cancelation of blood donation drives. If you would like to learn more, please click in the link below.  



Novartis, Incyte Set to Roll JAK Inhibitor Jakafi Into COVID-19 Clinical Trial 

Drugmakers across the board are rolling already approved drugs into late-stage clinical trials in an effort to find a speedy therapy for COVID-19. Now, two more are joining the party, with Swiss drugmaker Novartis and partner Incyte set to test their blockbuster JAK inhibitor.Novartis and Incyte will initiate a phase 3 clinical trial for Jakafi––marketed as Jakavi abroad––to test it as a treatment for cytokine storm, an immune overreaction that causes respiratory complications in severe COVID-19 patients, the Swiss drugmaker said in a release.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.